Fresh analysis suggests that individuals who discontinue new GLP-1 drugs like Wegovy and Mounjaro can put back on shed pounds far faster than those who stop traditional diet and exercise plans.
Published data in a major health publication shows that while obese people often shed about a fifth of their body weight while undergoing treatment, the mass is regained at an estimated rate of nearly a kilo each month after stopping.
"People purchasing these medications must be informed of the risk of quick weight regain when the therapy ends," warns lead investigator Dr. Susan Jebb.
That rate of recovery means a return to original mass in about 18 months.
Analyzing Treatments
The study, which looked at 37 of studies involving over 9,000 of patients, contrasted the results of GLP-1 agonists with conventional dieting.
Researchers emphasize that individuals who lose weight through diet and exercise typically have a less rapid weight regain—approximately 0.1 kg a month—after stopping.
Understanding the Quick Rebound
Experts suggest the mechanism of the injections is key to understanding the amplified rebound.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which controls hunger.
"Sustained high doses of the hormone levels far above than the body's typical production might result in the body to produce less of its own natural hormone, and may also lessen sensitivity to its effects," said Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication means hunger is unsuppressed, making binge eating far more likely."
A Lifelong Issue?
Health authorities recommend the jabs for individuals with weight-linked medical conditions, alongside prescribed lifestyle changes.
Many experts argue that, given the high risk of relapse, the therapy should be considered ongoing.
This opinion is supported by pharmaceutical companies, who note that the findings "emphasize the long-term nature of obesity," similar to managing conditions like high blood pressure.
Patient Experiences
Individuals who have discontinued the medication describe a sudden resurgence of hunger.
"It was like a switch that goes on and I was suddenly extremely hungry," recalled one woman.
This challenge is worsened if users have not adopted sustainable dietary or behavioural modifications during treatment.
Widespread Adoption
Survey data show that millions of adults in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Adoption is greater among females than men.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion access the drugs through private healthcare rather than the NHS.
Finally, experts stress that while these medications are effective tools for weight loss, they are not a permanent solution and lasting health benefits relies on integrated behavioural support.